AIDS policy chief Fleming outlines progress achieved, challenges ahead. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

AIDS policy chief Fleming outlines progress achieved, challenges ahead. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Policy Law. 1995 Mar 10;10(4):10-1. Unique Identifier : AIDSLINE AIDS/95700221

Abstract: Patricia S. Fleming, National AIDS Policy Director, addressed the HIV Infection in Women Conference in February 1995 about the progress made to improve HIV care for women and the difficult challenges that must be confronted in the years ahead. Fleming states that womens' health in general, and HIV in particular, is being taken more seriously and is more of a top priority of the Federal government. Researchers are now confirming that women are more susceptible to HIV transmission during heterosexual intercourse than are men. This is shown in part by the increasing rate of cases in women in the U.S.: cases are rising at a rate of 17 percent a year. AIDS is now the leading cause of death among Americans between 25 and 44 years old. AZT research has shown its effectiveness in preventing perinatal HIV transmission, but the short- and long-term effects of AZT treatment are unknown, although research is beginning in this area. Meanwhile, the Centers for Disease Control and Prevention (CDC) is now releasing guidelines to help women and health care professionals make the best decisions regarding counseling and HIV testing in pregnant women. Fleming views mandatory testing as ill conceived because it may drive some women away from prenatal care. She states that experience shows counseling and voluntary testing have produced good results. It is the government's responsibility to work with organizations to find ways to disseminate prevention information and to see that the best research is funded and the results widely disseminated.

Keywords: *Acquired Immunodeficiency Syndrome/DIAGNOSIS/DRUG THERAPY/ TRANSMISSION Adolescence Adult AIDS Serodiagnosis/LEGISLATION & JURISPRUD Child Disease Susceptibility Female Human Pregnancy *Women's Health Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLE
950930
M9591272

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .